Receptor Binding Affinity Explained for Peptides (2026): What Kd, On-Rate and Off-Rate Actually Mean
Affinity is the single number researchers reach for to describe how tightly a peptide grips its receptor — but it hides as much as it reveals. A research-framed explainer of Kd, on-rate, off-rate, potency vs affinity, and why selectivity matters more than a small number.
Affinity is the number researchers reach for first when they want to describe how a peptide interacts with its receptor — a single value that supposedly captures "how well it works." It is genuinely useful, and it is also genuinely misleading when read in isolation. This is a research-use explainer of what binding affinity actually measures, the rate constants hiding underneath it, and why selectivity and kinetics often matter more than a small number on a spec sheet.
Everything below is receptor pharmacology — a property of how molecules bind, measured in controlled assays. Nothing here is a claim about effects in people, and no compound is referenced for human use. Research and education only.
What affinity actually is
Binding affinity describes how strongly a peptide associates with its receptor at equilibrium — the steady state reached when binding and unbinding balance out. The standard measure is the dissociation constant, Kd, which is the concentration of free peptide at which half the available receptors are occupied.
The counterintuitive part is the direction: a lower Kd means tighter binding. A peptide with a Kd in the nanomolar range binds far more tightly than one in the micromolar range, because it achieves half-occupancy at a thousandfold lower concentration. Affinity is a property of the pair — this peptide with this receptor — not of the peptide alone. Change the receptor and the number changes.
The rate constants underneath: on-rate and off-rate
Kd is a ratio, and the two numbers it's built from carry information the ratio throws away:
- On-rate (kon) — how quickly the peptide finds and binds the receptor. Driven largely by how often the two molecules collide productively.
- Off-rate (koff) — how quickly a bound peptide lets go. This is the one researchers increasingly care about.
Kd equals koff divided by kon. Two peptides can share an identical Kd while behaving very differently: one binds fast and releases fast, the other binds slowly and clings. The second has a long residence time on the receptor — and residence time, not equilibrium affinity, often tracks better with how a ligand behaves in a dynamic system where concentrations rise and fall. A long off-rate can keep a receptor engaged well after free peptide has cleared, which is part of why pharmacokinetics and binding kinetics have to be read together. See peptide half-life and timing for how circulating lifetime interacts with this.
Affinity is not potency
This is the distinction that trips people up most. Affinity is how tightly a peptide binds. Potency is how much of it you need to produce a functional effect downstream. They are measured in different assays and they do not always agree.
A receptor system can amplify: a peptide might occupy only a fraction of receptors yet drive a near-maximal response because the signaling cascade has spare capacity. In that case potency outruns what raw affinity would predict. The reverse also happens — a tightly binding peptide that fails to trigger the conformational change needed for signaling binds beautifully and does little. Whether a bound peptide activates the receptor is a separate property entirely; that distinction between activation, blockade, and partial activation is the subject of agonist vs antagonist vs partial agonist.
A small Kd tells you a peptide grips the receptor. It tells you nothing about whether binding switches the receptor on, how selective the peptide is, or how long it stays bound. Affinity is one coordinate, not the whole map.
Why selectivity often matters more than a smaller number
Receptors come in families, and many peptides bind more than one member. Selectivity — how strongly a peptide prefers its intended target over related off-targets — is frequently the more decisive property in research.
Consider growth-hormone secretagogues, where some compounds are valued precisely because they engage one receptor cleanly while others are more promiscuous; the mechanistic detail is covered in growth hormone secretagogue mechanisms. A peptide that binds its target tightly but also grips three neighboring receptors introduces confounds into any assay, because you can no longer attribute an observed effect to a single pathway. A modestly lower affinity at the intended receptor, paired with clean selectivity against the rest of the family, is often the more useful research tool. Multi-receptor agonism is sometimes the goal rather than a flaw — but only when it's deliberate and characterized, not incidental.
How affinity is measured
Affinity values come from controlled binding assays — competition binding, saturation binding, or label-free methods such as surface plasmon resonance that read on-rate and off-rate directly rather than inferring them from equilibrium. The reported Kd is only as trustworthy as the assay conditions and the identity and purity of the peptide tested. A binding number measured on a mislabeled or impure preparation describes a mixture, not the molecule named on the label — which is why characterization is upstream of every affinity claim. The methods that confirm a peptide is what it claims to be are described in how peptides are synthesized and tested.
Putting it together for research
When you encounter an affinity figure, treat it as the opening of a question rather than the answer. Ask what receptor it was measured against, whether the off-rate was reported, whether a functional (potency) assay accompanies it, and how selective the peptide is across the receptor family. A peptide is characterized by a profile — affinity, kinetics, selectivity, and functional response together — and any single number pulled out of that profile is easy to over-read. You can review individual compounds and their documented receptor targets across the peptide reference library, explore research framed by research goal, and see how affinity-driven distinctions play out in the cognitive class where receptor selectivity is central. For the broader evidence framework, see our research overview.
Bottom line
Receptor binding affinity, expressed as Kd, tells you how tightly a peptide holds its receptor at equilibrium — lower Kd, tighter grip. But it hides the on-rate and off-rate that govern residence time, it is not the same as potency, and it says nothing about whether binding activates the receptor or how selective the peptide is. Read affinity as one coordinate inside a full pharmacological profile, and never separate it from the question of whether the material was correctly identified in the first place.
For research use only. This content is informational and does not constitute medical or dosing advice. All compounds referenced are for laboratory research use only — not for human consumption.
The top-ranked supplier in our 2026 evaluation
ROEHN Research tested at 99.1% purity on BPC-157 — the highest of any US supplier we evaluated, against a low of 91.3%. Readers save 15% on a first order with code FREE15.
- Cold-chain shipped
- Batch CoA in every box
- 30-day re-test policy
- 98%+ verified purity
Disclosure: Peptide Research Review maintains affiliate relationships with some of the suppliers we reference. Affiliate status has no influence on our research framing or our blinded, third-party lab evaluations. Read our editorial policy and methodology.
Get the full 38-sample purity report by email.
Eight US suppliers, thirty-eight samples, one blinded analytical lab. Every chromatogram, COA, and supplier score — delivered the moment you subscribe.
PDF delivered instantly. No account required. Unsubscribe anytime.
Peptide Contraindications and Interactions in Research (2026)
A research-framed look at how the literature reasons about contraindications and interactions for peptides — drawing on mechanism, overlapping pathways, and the regulated metabolic drugs — described as scientific reasoning, never as personal clinical guidance.
Receptor Desensitization & Tachyphylaxis in Peptides, Explained (2026)
Why a peptide's effect can fade with continuous exposure — a research-framed explainer of receptor desensitization, downregulation, and tachyphylaxis, and why pulsatile dosing and washout windows appear in study protocols.
Peptides vs Traditional Anabolics: A Research-Use Comparison (2026)
Growth-hormone secretagogue peptides and anabolic-androgenic steroids are different chemical classes acting through entirely different mechanisms. A research-framed comparison of structure, signaling, regulation, and verification.